Movement Alert|Regeneron Pharmaceuticals Intraday Rise 3.27% in Regular Trading, Liver-targeted siRNA Clinical Progress Supports Sentiment

Market Focus11-12

On November 12, Regeneron Pharmaceuticals rose 3.27% in regular trading, trading at $944.955/share, with turnover of $525 million.

The move coincided with continued market attention on the company’s liver-targeted siRNA program CIDEBsiRNA, whose early clinical data remained a key sentiment driver.

Recent disclosed data showed that after a single subcutaneous injection, liver fat was reduced by 58% to 80% at week 36 in a dose-dependent manner, versus a 2.9% decline in the placebo group. In addition, 93% of participants achieved at least a 30% reduction in liver fat, while ALT and AST indicators continued to improve. The latest regular-trading rise appears to reflect sustained investor focus on the program’s potential in metabolic dysfunction-associated fatty liver disease, following the company’s strong third-quarter results released in late October.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment